RFG Advisory LLC Has $254,000 Stake in Vertex Pharmaceuticals Incorporated $VRTX

RFG Advisory LLC lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 24.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 571 shares of the pharmaceutical company’s stock after selling 186 shares during the period. RFG Advisory LLC’s holdings in Vertex Pharmaceuticals were worth $254,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. United Services Automobile Association bought a new position in Vertex Pharmaceuticals in the 1st quarter worth approximately $2,933,000. Lee Johnson Capital Management LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $721,000. SteelPeak Wealth LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $10,059,000. Moody Lynn & Lieberson LLC raised its position in Vertex Pharmaceuticals by 1.4% in the 2nd quarter. Moody Lynn & Lieberson LLC now owns 58,077 shares of the pharmaceutical company’s stock worth $25,856,000 after purchasing an additional 822 shares during the last quarter. Finally, New England Research & Management Inc. bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $472,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th. Canaccord Genuity Group dropped their target price on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a research report on Wednesday, August 6th. Evercore ISI dropped their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research report on Thursday, September 11th. Stifel Nicolaus dropped their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a research report on Tuesday, August 5th. Finally, Royal Bank Of Canada dropped their target price on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $494.38.

Vertex Pharmaceuticals Stock Up 2.0%

VRTX opened at $416.81 on Monday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The company has a fifty day simple moving average of $395.46 and a 200 day simple moving average of $436.10. The stock has a market cap of $106.87 billion, a P/E ratio of 29.79 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the prior year, the company earned ($12.83) EPS. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.